Quantifying exploratory low dose compounds in humans with AMS.
Accelerator Mass Spectrometry is an established technology whose essentiality extends beyond simply a better detector for radiolabeled molecules. Attomole sensitivity reduces radioisotope exposures in clinical subjects to the point that no population need be excluded from clinical study. Insights in human physiochemistry are enabled by the quantitative recovery of simplified AMS processes that provide biological concentrations of all labeled metabolites and total compound related material at non-saturating levels. In this paper, we review some of the exploratory applications of AMS (14)C in toxicological, nutritional, and pharmacological research. This body of research addresses the human physiochemistry of important compounds in their own right, but also serves as examples of the analytical methods and clinical practices that are available for studying low dose physiochemistry of candidate therapeutic compounds, helping to broaden the knowledge base of AMS application in pharmaceutical research.
Vitalea Science, Inc, Davis, CA 95618, USA. stephen.dueker@vitaleascience.com
Stephen R
SR
Dueker
Le T
le T
Vuong
Peter N
PN
Lohstroh
Jason A
JA
Giacomo
John S
JS
Vogel
D000818:Animals; D002250:Carbon Radioisotopes; D002986:Clinical Trials as Topic / Q000379:methods*; D004305:Dose-Response Relationship, Drug; D015195:Drug Design; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods*; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000378:metabolism
D002250:Carbon Radioisotopes; D004364:Pharmaceutical Preparations